BioVie establishes $6.46M stock sale program
Rhea-AI Filing Summary
BioVie Inc. (BIVI) entered into a sales agreement with A.G.P./Alliance Global Partners to offer and sell, from time to time, shares of its Class A common stock with an aggregate offering price of up to $6,464,341 in an at-the-market offering under its effective Form S-3 shelf registration. The Agent may effect sales on or through The Nasdaq Capital Market or other U.S. trading markets, or in negotiated transactions, using commercially reasonable efforts on terms mutually agreed with BioVie. BioVie will pay the Agent a 3.0% commission on gross proceeds and reimburse specified expenses, and intends to use any net proceeds for general corporate purposes. The program will end upon the earlier of selling all Placement Shares, expiration of the registration statement on the third anniversary of its June 29, 2026 effectiveness, or termination of the agreement by either party; BioVie has no obligation to sell any shares and may suspend or terminate offerings at any time.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Aggregate offering price: $6,464,341
Sales agent commission: 3.0% of gross proceeds
Form S-3 effectiveness date: June 29, 2026
+2 more
5 metrics
Aggregate offering price
$6,464,341
Maximum aggregate offering price of Placement Shares under the at-the-market program
Sales agent commission
3.0% of gross proceeds
Commission payable to A.G.P./Alliance Global Partners for Placement Shares sold
Form S-3 effectiveness date
June 29, 2026
Date the Registration Statement on Form S-3 was declared effective
Sales agreement date
September 11, 2026
Date BioVie entered into the sales agreement with A.G.P./Alliance Global Partners
Registration statement file number
333-296924
File number of the Form S-3 used for the at-the-market offering
Key Terms
at-the-market offering, Registration Statement on Form S-3, prospectus supplement, Rule 415, +2 more
6 terms
at-the-market offering financial
"may sell the Placement Shares by any method deemed to be an “at-the-market offering”"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
Registration Statement on Form S-3 regulatory
"offered and sold pursuant to the Company’s Registration Statement on Form S-3"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
prospectus supplement regulatory
"and a prospectus supplement that was filed with the SEC on September 11, 2026"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Rule 415 regulatory
"as defined in Rule 415 promulgated under the Securities Act of 1933"
Rule 415 is a U.S. Securities and Exchange Commission regulation that lets a company register securities ahead of time and then offer them for sale in pieces over an extended period under a “shelf” registration, so offerings can be launched quickly when market conditions suit the issuer. For investors, it signals that management has a ready way to raise capital fast—useful for seizing opportunities but potentially dilutive to existing shareholders, like a company pre-loading a credit line it can tap as needed.
Securities Act of 1933 regulatory
"Rule 415 promulgated under the Securities Act of 1933, as amended"
general corporate purposes financial
"intends to use the proceeds from the sale of the Placement Shares, if any, for general corporate purposes"
"General corporate purposes" refer to the broad range of activities and expenses a company can use its funds for to support its overall operations and growth. This can include things like paying bills, investing in new projects, or strengthening its financial position. For investors, understanding this term helps clarify how a company plans to use its resources to sustain and expand its business over time.
Offering Details
ATM
Offering
Offering Type
ATM
Use of Proceeds
General corporate purposes
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity offering did BIVI announce on September 11, 2026?
BioVie Inc. announced a sales agreement with A.G.P./Alliance Global Partners for an at-the-market offering of Class A common stock with an aggregate offering price of up to $6,464,341 under its effective Form S-3 shelf registration statement.
How will BioVie (BIVI) use the proceeds from this at-the-market program?
BioVie states that it intends to use the proceeds from the sale of the Placement Shares, if any, for general corporate purposes, without further specification in this disclosure.
What fees will BioVie (BIVI) pay under the sales agreement with A.G.P./Alliance Global Partners?
Under the sales agreement, BioVie will pay the Agent a 3.0% commission on the gross proceeds from Placement Shares sold and has agreed to reimburse specified expenses incurred by the Agent.
When does BioVie’s (BIVI) at-the-market offering program end?
The offering ends upon the earlier of sale of all Placement Shares, expiration of the Form S-3 registration statement on the third anniversary of its June 29, 2026 effectiveness, or termination of the sales agreement by BioVie or the Agent.
On which registration statement is BioVie’s (BIVI) ATM offering based?
The Placement Shares will be offered and sold pursuant to BioVie’s Registration Statement on Form S-3 (File No. 333-296924), filed with the SEC on June 18, 2026 and declared effective on June 29, 2026, plus a prospectus supplement dated September 11, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
